CERENOME INC
CNSYNASDAQ🏆 #4892 by market capEarnings Oct 28US Equity
$1.86▼ $0.13 (−7.00%)
Market closed · at closeTrack CNSY
Get earnings, price moves & breaking news on Telegram
24h▼ 7.0%
7d▼ 5.1%
14d▼ 8.4%
30d▼ 34.7%
ytd▼ 85.4%
1y▼ 89.0%
🏦Market Cap
$13M
Small Cap
📈Revenue Growth (YoY)
-10.5%
Declining
📊Gross Margin
89.6%
High
💵FCF Margin
-560.3%
Thin
⚖️P/S Ratio
3.3x
Fair
Otter Score
80
Good
Trading Snapshot
- Day Range
- $1.84 – $1.89
- 52-Week Range
- $1.86 – $23.50
- Volume
- $2.52B
- Avg Volume
- $2.19B
- Shares Outstanding
- 6.9M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $411,000
- P/E Ratio
- -0.0
- P/S Ratio
- 3.3x
- EPS (TTM)
- $-3.85
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1319516.7%
Why Investors Own CNSY
- ✓High-growth profile — revenue up +19.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CERENOME INC
CNSYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5M▼ −10.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.5%▲ +7.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▲ +4.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▲ +94.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.1M▲ +1319516.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$11M YoY
StockOtter · stockotter.spaceAbout CERENOME INC
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026
Latest News & Updates
🚀
Barron’s·2h ago
CERENOME INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift CNSY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
CERENOME INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.